Profusa, Inc.

PFSA

US74319X2071

Medical Equipment, Supplies & Distribution

End-of-day quote Nasdaq Other stock markets 15/04/2026			5-day change	1st Jan Change
0.6630 ^USD	-4.59%		-45.66%	-91.56%

04-16	Profusa, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-06	Profusa expands into multi-billion dollar precision diagnostics market with $30m letter of intent for a PanOmics platform	RE

Profusa terminates Bitcoin Treasury Reserve Strategy and to liquidate Bitcoin holdings

Published on 03/13/2026 at 02:32 pm +04

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Profusa, Inc.

04-16	Profusa, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-06	Profusa expands into multi-billion dollar precision diagnostics market with $30m letter of intent for a PanOmics platform	RE
04-06	Profusa, Inc. entered into a non-binding letter of intent to acquire Certain assets of Bio Insights LLC from Bio Insights LLC for $30 million.	CI
03-27	Profusa Inc - enters amendment to promissory note with Northview Sponsor I LLC on March 20, 2026 - SEC filing	RE
03-13	Profusa terminates Bitcoin Treasury Reserve Strategy and to liquidate Bitcoin holdings	RE
02-19	Profusa, Inc. Raises Revenue Guidance for 2026	CI
02-19	Profusa Receives Purchase Orders for Lumee? Tissue Oxygen Monitoring	CI
02-13	Profusa and Mayo Clinic collaborate to advance high-impact clinical applications of oxygen monitoring technologies	RE
02-13	Profusa, Inc. and Mayo Clinic Collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies	CI
01-29	Profusa, Inc. Presents Positive Us- Study Clinical Results At Leipzig Interventional Course 2026	CI
01-16	Profusa, Inc. Launches Lumee?? Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue	CI
12-31	Profusa, Inc. Bolsters European Commercial Network with New French Distributor, Medsell	CI
12-30	Profusa Restructures Senior Secured Convertible Notes; Shares Jump Pre-Bell	MT
12-22	TransCode Therapeutics, Inc. Appoints Jack Stover to its Board and Announces Committee Changes, Effective December 19, 2025	CI
12-15	Profusa U.S. study met primary end points as presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025	RE

NorthView Acquisition Corporation is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The Company intends to focus its search on businesses that are focused on the biopharmaceutical, medical technology/medical device, and diagnostics space, which aligns with the management teamâ€™s experience in operating health care companies and in drug and device technology development as well as diagnostic and other services. The Company is not engaged in any business operations and has not generated any revenue.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company